Management of patients with inflammatory bowel disease and spondyloarthritis - Université de Lorraine Access content directly
Journal Articles Expert Review of Clinical Pharmacology Year : 2017

Management of patients with inflammatory bowel disease and spondyloarthritis

Abstract

Introduction: More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Expert commentary: The coexistence of IBD and SpA generates challenges and opportunities for both the gastroenterologist and the rheumatologist. The potential of drugs with a gut-specific mode of action in the treatment of IBD-related arthritis warrants further exploration
Fichier principal
Vignette du fichier
pouillon.pdf (1.26 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01715137 , version 1 (22-02-2018)

Identifiers

Cite

Lieven Pouillon, Peter Bossuyt, Joke Vanderstukken, David Moulin, Patrick Netter, et al.. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Review of Clinical Pharmacology, 2017, 10 (12), pp.1363-1374. ⟨10.1080/17512433.2017.1377609⟩. ⟨hal-01715137⟩
171 View
1616 Download

Altmetric

Share

Gmail Facebook X LinkedIn More